Sarge, what this deal is going to do is preserve the bottom line for SPL, because the R&D teams that currently are being paid by SPL are reaching the end of their work as the Ph2 Trials are all but done and it seems there is no other potential products in the pipeline within SPL.
This R&D team will now shift focus to this new product that will be paid for by Petalion. Therefore, cash burn at SPL will reduce and therefore less risk of cap raises.....
SPL Price at posting:
14.0¢ Sentiment: Hold Disclosure: Held
